Skip to main content

Cancer is personal.
Cancer therapy should be, too.

Our multimodal AI test provides individualized results, enabling personalized treatment decision-making between clinicians and patients.

hero_prostate-test
Right Image
ArteraAI Included in the 2024 NCCN Guidelines® for Prostate Cancer

ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today its inclusion in the newly released NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer. The ArteraAI Prostate Test is the only test included for its predictive performance.

Learn More
CMS payment rate established for ArteraAI prostate cancer test

The Centers for Medicare & Medicaid Services (CMS) have established a payment rate for the ArteraAI prostate cancer test, a multimodal artificial intelligence (MMAI) biomarker test that can predict therapy benefit and prognosticate long-term outcomes of treatment in patients with localized prostate cancer, according to a news release from ArteraAI, the developer of the test.1

Learn More
AUA 2024 Annual Meeting
5/3/2024 to 5/6/2024

AUA 2024 Annual Meeting

Henry B. González Convention Center, San Antonio TX

The Annual Meeting, in its 119th year, is the largest gathering of urologists in the world, providing unparalleled access to groundbreaking research, new guidelines and the latest advances in urologic medicine.

Learn More

AI enhances cancer therapy treatment decisions

Artera leverages advanced technology to personalize treatment decisions for prostate cancer, which has the highest prevalence of any non-skin cancer in the human bodyAmerican Cancer Society. Facts & Figures 2023. American Cancer Society. Atlanta, Ga. 2023., and is the most frequently diagnosed cancer across 112 countries.Sung et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021: 71: 209- 249. https://doi.org/10.3322/caac.21660

HomeHome

1 in 8

The number of men who will be diagnosed with prostate cancer in their lifetime and who need more precise and personalized treatment options for optimized outcomes.American Cancer Society. Facts & Figures 2023. American Cancer Society. Atlanta, Ga. 2023.

2x

African American men are more likely to develop prostate cancer, and are twice as likely to succumb to the disease.Lillard et al. 2022. Racial disparities in Black men with prostate cancer: A literature review. Cancer, 128: 3787-3795. https://doi.org/10.1002/cncr.34433 Artera multimodal artificial intelligence (MMAI) models were developed to allow for more diversity in data.Roach et al. 2022. Prostate cancer risk in African American men evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology phase III clinical trials. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 108-108. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.108

3%

Since 2014, the number of prostate cancers diagnosed each year has increased by 3%.Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17‐48. https://doi.org/10.3322/caac.21763 Using Artera to predict treatment benefit is more critical than ever.

specialized-tools

Specialized tools to support personalized clinical care

The first and only AI test to be recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer for predictive and prognostic performanceReferenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer V.3.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed March 12, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. NCCN, National Comprehensive Cancer Network.

Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers AI-enabled predictive and prognostic cancer tests, including the first of its kind for patients with localized prostate cancer: ArteraAI Prostate Test.

Robust clinical data provides better results

better-data

The ArteraAI Prostate Test is intended to identify patients who will benefit from therapy intensification and help guide treatment decisions for men with localized prostate cancer. By learning from digital pathology images and ingesting clinical data, our test can predict therapy benefit and determine prognosis for a patient. Rather than focusing on one clinical attribute, the AI analyzes multiple characteristics of the individual patient and accomplishes things that conventional techniques and computers cannot do alone.

graphic_personalization

Artera biomarkers can predict therapeutic benefit and prognosticate long-term outcomes to enable cancer therapy personalization.

Icon

Our MMAI biomarker test leverages a unique, clinically validated algorithm that assesses digital images from a patient’s biopsy and learns from a patient's clinical data.

graphic_clock

Test results are generated without consuming tissue and are available to review within 2-3 days after receipt of the patient's specimen.

Empowering doctors with predictive and prognostic data

400+

Multinational institutions

9

Phase 3 clinical trials used for validation

4.5

Terabytes of image data

Artera supports both clinicians and patients

Individualized treatment plans

The ArteraAI Prostate Test is able to predict if a patient will benefit from a specific treatment, allowing for a more personalized approach to cancer therapy.

Shared decision-making

The test supports shared decision-making for clinicians and patients, as it provides results that are specific to the individual patient.

Diversity in data

Our MMAI models were developed with cohorts comprising about 20% African American patients, which is reflective of the 16% prevalence of this disease in the African American population.

Does Not Consume Tissue

The ArteraAI Prostate Test does not consume tissue. Artera uses a patient's existing pathology slides and digitizes them for the AI model.

Expedited Treatment Planning

Our standardized report provides both predictive and prognostic results to support personalized treatment. The speediness of AI computation allows results to be shared within 2-3 days after receipt of the patient's specimen.

AI That Empowers Physicians

The test provides individualized results that better inform physicians in the treatment decision-making process, allowing them to practice with more confidence.

We're passionate We're passionate small

We’re passionate about personalizing cancer care

Driven by integrity, innovation, and the advancement of medical technology, our team of experts is passionate about developing AI tools that help enable clinicians to deliver individualized treatment plans.

Meet the collaborators who make our work possible

Recent news & insights from Artera

How can Artera bootstrap a new AWS region within hours?

Setting up the infrastructure for a product line in an entirely new region with over 340 distinct AWS resources could easily take weeks. At Artera, it takes hours.

LUGPA Regional Meeting

LUGPA's regional meetings offer unique, cutting edge content to better navigate the changing healthcare landscape. These intimate forums provide opportunities to eng [...]

Analytical Validation of a Clinical Grade Prognostic and Classification Artificial Intelligence Laboratory Test for Men with Prostate Cancer

This is the first study of which we are aware to describe the analytical validation (AV) of clinical grade artificial intelligence (AI) algorithms for a commercially [...]

Left Icon

Order the ArteraAI
Prostate Test for
your patient.

Start your order
Right Icon

Be your own advocate!
Share this information
with your doctor today.

Send to doctor